Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

NCT ID: NCT04292769

Last Updated: 2020-03-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-21
• Study Completion Date: 2023-01-20

Brief Summary

1. Screening stage

2. Evaluation of disease

3. Grouping of patients

4. Infusion of cells

5. Surveillance of adverse effect

Detailed Description

1. Screening stage：All patients must be confirmed by pathology priorily and reachead remission after surgery or chemo- or radiotherapy. All criteria patients must sign informed consent in advance.

2. Evaluation of disease: Systematically assessment of tumor burdern and Physical fitness of all patients.

3. Cell preparation：At least one month after the end of the last chemotherapy, 100ml of peripheral blood was collected, and PBMCs were separated and extracted in the tens of thousands and local hundreds of clean laboratories and DC-CIK cells were prepared.

4. Baseline assessment: Systematically assess various biochemical indicators. Those who do not meet the infusion criteria will withdraw from the study after being confirmed by researchers.

5. Study group: All subjects were randomly divided into test group and control group. The test group was treated with decitabine. The course of treatment was a total of 5 times.

6. Infusion：During cell culture and before transfusion, cells should be subjected to strict quality control tests such as bacteria, fungi, mycoplasma, endotoxin, cell activity, DC and T cell identification, etc. The transfusion can be approved only after the quality control is qualified.

7. Adverse reaction monitoring: DC-CIK infusion was used to closely observe changes in subjects' blood pressure, body temperature, blood routine, blood biochemistry, electrolytes, coagulation, cytokines and organ functions.

8. After the trial is completed, the patient's survival information will be followed up every 3 months by telephone or by visiting the test center.

Conditions

Malignant Neoplasm

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Decitabine combined with DC-CIK

Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.

Group Type: EXPERIMENTAL

Decitabine

Intervention Type: DRUG

Decitabine 10mg / d, intravenous administration d-5 ～ d-1

DC-CIK

Intervention Type: BIOLOGICAL

Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;

DC-CIK

Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.

Group Type: ACTIVE_COMPARATOR

DC-CIK

Intervention Type: BIOLOGICAL

Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;

Interventions

Decitabine

Decitabine 10mg / d, intravenous administration d-5 ～ d-1

Intervention Type: DRUG

DC-CIK

Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged 18-70 years (including 18 and 70 years);

2. Pathological and histological examination confirmed a malignant solid tumor;

3. Patients with ECOG score <2, estimated survival time> 3 months.

4. Patients with solid tumors have cleared their lesions after treatment, and are unsuitable or unwilling to receive other anti-tumor treatments such as chemotherapy and radiotherapy;

5. Patients did not receive any anti-cancer treatment such as chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) within 2-4 weeks before enrollment, and their previous treatment-related toxicities have recovered to <1 (hair loss) , Except for low-level toxicity such as peripheral neuritis);

6. The patient's venous channel is unobstructed, which can meet the needs of intravenous drip;

7. Patients voluntarily participate and sign informed consent, and follow the research treatment plan and visit plan.

Exclusion Criteria

• 1. Patients use large doses of hormones (except for patients using inhaled hormones) within 1 week before enrollment; 2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. Patients treated with other cellular immune products (DC, T, NK, and CAR-T, etc.); 4. Patients have uncontrollable infections within 4 weeks before enrollment; 5. Active HBV DNA> 1000copy / mL / Hepatitis C virus (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 6. Patients participated in other clinical studies within 6 weeks before enrollment; 7. Patients with mental illness; 8. Patients with a substance abuse / addiction and medical, psychological or social conditions that may interfere with the study or influence the evaluation of the study results; 9. Alcohol dependence in patients; 10. Women who are pregnant (positive urine / blood pregnancy study) or breastfeeding; men or women with a pregnancy plan in the past year; patients cannot guarantee effective contraception during the study period 11. At the discretion of the investigator, the patient has other unsuitable conditions.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Li Yu

OTHER

Sponsor Role: lead

Responsible Party

Li Yu

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Shenzhen university general hospital

Shenzhen, , China

Site Status: RECRUITING

Countries

China

Facility Contacts

LI Yu, Doctor

Role: primary

liyu301@vip.163.com

+8675521839215

Other Identifiers

ONCO-CIK-001

Identifier Type: -

Identifier Source: org_study_id